Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB2 | O60825 | 2/20 | 0.40 |
| ▸ | PFKFB1 | P16118 | 2/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13818804 | 1.00 | PFKFB2 (0.40) | PFKFB2PFKFB1PFKFB3SCN3ASCN9A | |
| SCHEMBL439086 | 1.00 | PFKFB2 (0.40) | PFKFB2PFKFB1PFKFB3SCN3ASCN9A | |
| SCHEMBL403972 | 0.97 | CTSK (0.38) | PFKFB2PFKFB1PFKFB3 | |
| SCHEMBL403973 | 0.97 | CTSK (0.38) | PFKFB2PFKFB1PFKFB3 | |
| SCHEMBL13818803 | 0.97 | CTSK (0.38) | PFKFB2PFKFB1PFKFB3 | |
| SCHEMBL400769 | 0.96 | PFKFB2 (0.41) | PFKFB2PFKFB1PFKFB3SCN3ASCN9A | |
| SCHEMBL1109269 | 0.94 | — | — | |
| SCHEMBL1109424 | 0.90 | SCN3A (0.47) | PFKFB2PFKFB1PFKFB3SCN3ASCN9A | |
| SCHEMBL13825558 | 0.90 | SCN3A (0.47) | PFKFB2PFKFB1PFKFB3SCN3ASCN9A | |
| SCHEMBL10286757 | 0.87 | SCN3A (0.44) | SCN3ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | PFKFB2 411/4885PFKFB1 222/4885PFKFB3 457/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | PFKFB2 411/4885PFKFB1 222/4885PFKFB3 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.